{"id":34080,"date":"2025-08-14T10:30:00","date_gmt":"2025-08-14T14:30:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=34080"},"modified":"2026-04-18T13:18:55","modified_gmt":"2026-04-18T17:18:55","slug":"beyond-the-bench-transforming-biopharmaceutical-strategy-with-patent-intelligence","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-bench-transforming-biopharmaceutical-strategy-with-patent-intelligence\/","title":{"rendered":"Biopharma Patent Intelligence: The Definitive Guide to Turning IP Data into Pipeline and Deal Advantage"},"content":{"rendered":"\n

Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

The cost to bring a new molecular entity to market has crossed $2.5 billion on a capitalized basis when accounting for the cost of failures across a typical portfolio. That figure, from the widely cited DiMasi et al. analysis published in the Journal of Health Economics, includes the opportunity cost of capital tied up across the average 10-to-12-year development timeline. It does not fully capture the post-approval investment required for Phase IV commitments, label expansions, and the manufacturing scale-up that regulators increasingly expect before first commercial launch.<\/p>\n\n\n\n

Attrition rates compound this problem. The probability that a compound entering Phase 1 trials reaches FDA approval sits below 10%. Phase 2 is the most brutal filter: oncology programs fail at Phase 2 roughly 60% of the time, and central nervous system drugs fail even more often, historically around 80% at that stage. Late-stage failures are not just expensive; they reset timelines, trigger impairment charges, and in small-cap biotechs, can trigger covenant breaches on milestone-linked credit facilities.<\/p>\n\n\n\n

Eroom’s Law and the Structural Productivity Problem<\/strong><\/h3>\n\n\n\n

The R&D productivity crisis has a name: Eroom’s Law, the deliberate inversion of Moore’s Law. The number of new drugs approved per billion dollars of inflation-adjusted R&D spending has roughly halved every nine years since the 1950s. The reasons are structural. Regulatory evidentiary thresholds have risen. Target biology in the remaining disease areas is genuinely harder. The “easy” targets in cardiovascular disease, bacterial infection, and first-generation CNS indications have been addressed. What remains, including Alzheimer’s pathology, solid tumor microenvironment biology, and gain-of-function rare genetic disorders, demands mechanistic specificity that preclinical models routinely overpredict.<\/p>\n\n\n\n

The practical consequence for portfolio managers and R&D leads is that intuition-based target selection, unanchored from external intelligence, is a losing strategy at current capital costs. You need a systematic method for identifying where to place bets before you fund a discovery program. Patent data is the most granular and most current dataset available for making that call.<\/p>\n\n\n\n

The Patent Clock and the Revenue Treadmill<\/strong><\/h3>\n\n\n\n

A composition-of-matter patent filed at the time of lead candidate identification typically expires 20 years from the priority date. By the time a drug reaches market, 10 to 13 years of that term are already consumed. The effective market exclusivity window is therefore 7 to 10 years for most products, shorter for those with protracted Phase 3 programs or extended regulatory review.<\/p>\n\n\n\n

That window drives every major commercial decision. It determines the pricing ceiling a manufacturer can defend against payer pressure. It sets the horizon for peak-sales modeling. It anchors the net present value (NPV) calculations that determine whether a program clears an internal hurdle rate. When that clock expires, the revenue cliff is steep: branded small molecules typically lose 80 to 90% of their unit volume within 12 months of generic entry. Biologics lose market share more slowly, but biosimilar uptake is accelerating as payer formulary management becomes more aggressive and as the 12-year exclusivity period under the Biologics Price Competition and Innovation Act (BPCIA) comes into play for a growing list of reference products.<\/p>\n\n\n\n

Key Takeaways: The Economics of Risk<\/strong><\/h3>\n\n\n\n

Patent intelligence is not a legal nicety. Given development costs, attrition rates, and the compressed effective exclusivity window, every resource allocation decision in a biopharma portfolio carries patent-dependent assumptions. Teams that analyze the patent landscape before committing discovery spend avoid the most expensive category of error: advancing a program into a space so legally encumbered that a clear commercial path does not exist.<\/p>\n\n\n\n

\n\n\n\n

Part 2: What Patent Data Actually Contains (And Why Most Teams Read It Wrong)<\/strong><\/h2>\n\n\n\n

The global patent database holds over 100 million documents across the European Patent Office (EPO), the USPTO, the Japan Patent Office (JPO), the China National Intellectual Property Administration (CNIPA), and the World Intellectual Property Organization (WIPO) PCT system. Most life sciences professionals have seen a patent. Far fewer have developed a systematic method for extracting the strategic intelligence buried inside one.<\/p>\n\n\n\n

The Anatomy of a Pharmaceutical Patent: Beyond the Front Page<\/strong><\/h3>\n\n\n\n

Patent documents have a defined structure. The front page contains bibliographic data: application number, priority date, assignee, inventors, and the International Patent Classification (IPC) codes that categorize the technology. These front-page elements are the inputs for most commercial patent database searches. They are useful but not sufficient.<\/p>\n\n\n\n

The specification is where the real intelligence lives. It is a legally mandated full disclosure of the invention: the problem being solved, the mechanism of action, the chemical or biological structure of the compound, the synthetic route or cell-line expression system, and the experimental data. Specifically, patent specifications in the pharmaceutical space regularly include: in vitro binding data against the target receptor, in vivo pharmacokinetic parameters (half-life, bioavailability, Cmax), efficacy data from rodent or primate disease models, and dose-finding results. For biologics, specifications frequently disclose CDR sequences, glycosylation profiles, and manufacturing process parameters at a level of detail that does not appear in any peer-reviewed publication until years later.<\/p>\n\n\n\n

The claims are the legal boundary of the monopoly. Claim 1 is usually the broadest independent claim. Dependent claims narrow the invention by adding specific features. The scope of Claim 1 determines whether a competitor can design around the patent or must license it. A composition-of-matter claim that covers a genus of compounds is far harder to design around than a method-of-use claim covering a specific dosing regimen. Understanding claim scope requires patent literacy, but it does not require a law degree. Any scientist who has read a handful of patents with attention to claim language can develop the analytical fluency to assess breadth versus narrowness.<\/p>\n\n\n\n

Patent Types and Their Strategic Weight<\/strong><\/h3>\n\n\n\n

Composition-of-matter patents cover the molecule or biologic itself. They are the highest-value form of pharmaceutical patent protection because they preclude competitors from using the same compound for any purpose, not just the approved indication. For small molecules, this means covering the specific chemical structure, often including a range of stereoisomers, salts, esters, and prodrugs. For biologics, composition claims typically cover the amino acid sequence and may extend to a class of antibodies sharing a defined epitope binding profile.<\/p>\n\n\n\n

Method-of-use patents cover the application of a compound to treat a specific disease in a defined patient population. These are the basis of indication expansion strategies. Sildenafil, developed by Pfizer originally for hypertension, generated its commercial franchise through a method-of-use patent on erectile dysfunction treatment. The compound itself was known. The new application was patentable. Method-of-use patents are also the mechanism through which precision medicine stratification creates new IP. A patent claiming the use of a PD-L1 inhibitor specifically in patients with a defined tumor mutational burden threshold protects not just the drug but the clinical strategy built around a companion diagnostic.<\/p>\n\n\n\n

Formulation patents cover specific pharmaceutical preparations: extended-release matrices, nanoparticle encapsulation, lipid nanoparticle (LNP) delivery systems, liposomal formulations, fixed-dose combination tablets, and device-drug combinations like autoinjectors or prefilled syringes. These are the primary tools of evergreening strategy, discussed at length in Part 7.<\/p>\n\n\n\n

Process patents, particularly in biologics, can be as commercially important as composition claims. The upstream bioprocessing conditions, cell culture media composition, purification column chromatography sequences, and formulation buffer chemistry for a monoclonal antibody are collectively the manufacturing fingerprint that regulators use to assess biosimilarity. Competitors seeking to launch a biosimilar must demonstrate that their independent manufacturing process produces a molecule that is ‘highly similar’ to the reference product with no clinically meaningful differences. A dense thicket of process patents around those manufacturing variables forces a biosimilar developer either to design around each one or to accept licensing costs that erode the economics of entry.<\/p>\n\n\n\n

Patent Families and Global Filing Footprint as Commercial Intent<\/strong><\/h3>\n\n\n\n

A patent family aggregates all applications filed across multiple national or regional offices that share a common priority application. The geographic scope of a family is a direct expression of commercial intent. Filing, prosecuting, and maintaining patents in a major market costs real money: USPTO filing and prosecution through grant can run $15,000 to $30,000 per application; EPO validation across a standard set of European member states adds another $20,000 to $40,000; JPO, CNIPA, and other tier-one markets add further cost. No company maintains patents in markets it does not intend to commercialize or license.<\/p>\n\n\n\n

For competitive analysis, a competitor’s filing footprint tells you which markets they see as high-priority commercial targets. For smaller biotechs, a narrow footprint, often US-only, signals either capital constraints or a strategy aimed at attracting a global partner who will extend the filing scope as part of a licensing deal. When you are evaluating a potential in-licensing asset and see US-only filings, the interpretation should be tested directly in diligence: is this a budget limitation or a deliberate decision based on market prioritization?<\/p>\n\n\n\n

Key Takeaways: Reading Patent Data<\/strong><\/h3>\n\n\n\n

The value in a patent is in its specification and claims, not its front page. IP teams and strategy functions that have developed fluency in reading the technical substance of patents, not just searching and counting them, have a structural analytical advantage. The global filing footprint of a patent family is quantifiable evidence of a competitor’s market strategy.<\/p>\n\n\n\n

\n\n\n\n

Part 3: IP Valuation as a Core Asset: How to Put a Number on a Patent Estate<\/strong><\/h2>\n\n\n\n

Patent portfolios appear on balance sheets as intangible assets, typically at amortized cost. That accounting treatment systematically understates their economic value and provides almost no decision-relevant information for portfolio managers trying to assess which assets to acquire, develop, or divest. A more rigorous approach to IP valuation, anchored in commercial cash flow analysis rather than cost basis, gives both internal strategy teams and external investors a sharper picture of a company’s true asset base.<\/p>\n\n\n\n

The Three Methods: Income, Market, and Cost Approaches<\/strong><\/h3>\n\n\n\n

The income approach projects the future cash flows attributable to the patent-protected product, discounts them at a risk-adjusted rate, and treats the resulting NPV as the patent’s value. This is the most commercially meaningful method for pharmaceutical patents because it directly ties the IP to revenue. The core inputs are: peak sales estimates by indication and geography, probability-of-approval assumptions by development stage (using published clinical success rates segmented by therapeutic area and mechanism), the exclusivity window defined by patent expiration dates and expected generic entry timing, and a discount rate that reflects both the cost of capital and program-specific risk.<\/p>\n\n\n\n

A critical variable in this calculation is the ‘relief from royalty’ adjustment. If the company did not own the patent and had to license the technology from a third party, what royalty rate would it pay? The estimated royalty rate, multiplied by projected royalty-bearing revenue, and then discounted to present value, yields an estimate of the patent’s standalone economic contribution. Industry royalty benchmarks vary by asset type: composition-of-matter patents for first-in-class biologics typically command rates between 8% and 15% of net sales; method-of-use patents for incremental improvements command lower rates, often 2% to 5%.<\/p>\n\n\n\n

The market approach looks at comparable transactions: what did buyers pay for similar IP in similar circumstances? In biopharma, this requires careful calibration. The market for patent licenses and asset acquisitions is illiquid and information-poor compared to public equity markets. Published deal databases, including DrugPatentWatch, BioMedTracker, and Citeline Pharma Intelligence, provide transaction comps that can be used to benchmark valuations, but the range of outcomes is wide and deal terms are highly structure-dependent.<\/p>\n\n\n\n

The cost approach calculates what it would cost to recreate the invention independently. In drug development, this is rarely the primary valuation method because the cost of drug discovery has minimal correlation with the commercial value of the output. A blockbuster discovered with modest expenditure is not worth less than an equivalent compound discovered after a decade of expensive screening.<\/p>\n\n\n\n

IP Valuation for Specific Asset Classes<\/strong><\/h3>\n\n\n\n

For a composition-of-matter patent on a first-in-class small molecule with Phase 2 proof-of-concept data in a large indication, current market-implied valuations in deal transactions typically run between $150 million and $600 million in upfront and near-term milestones, depending on indication size, competitive landscape density, and remaining patent life. The milestone tail, which can extend to $500 million to $1.5 billion in regulatory and commercial milestones for major indications, is contingent on events that require probability-weighting. The key IP-specific driver is how much of the remaining patent term coincides with the projected commercial peak: a drug with 12 years of exclusivity remaining at launch is substantially more valuable than the same drug with 6 years remaining.<\/p>\n\n\n\n

For a biologic, the valuation structure is more complex because IP protection comes from multiple overlapping sources. The composition patent covering the antibody sequence may have 8 years of life remaining, but the product may also be protected by the 12-year BPCIA exclusivity period from its biologics license application (BLA) approval date, by a dense family of formulation and process patents extending to 2035 or beyond, and by clinical use patents covering specific patient populations. Valuing this bundle correctly requires mapping each protection layer against the projected biosimilar entry timeline and modeling the revenue impact of each layer’s expiration.<\/p>\n\n\n\n

For a generic or biosimilar competitor doing the same analysis from the other side, the calculation is a question of entry economics: what is the probability of successfully challenging each patent layer, what is the expected timeline to market entry under different litigation scenarios, and what is the expected market share and price level that a first-wave generic or biosimilar entrant can capture?<\/p>\n\n\n\n

Key Takeaways: IP Valuation<\/strong><\/h3>\n\n\n\n

Patent portfolios are economic assets that standard accounting treatment misrepresents. Income-based valuation anchored to patent-adjusted NPV calculations, benchmarked against transaction comps, gives portfolio managers and deal teams a quantitative basis for asset prioritization and deal structuring. The specific variables that matter most are remaining patent term at projected launch, the density and defensibility of the secondary patent estate, and the probability and timing of generic or biosimilar entry under realistic litigation assumptions.<\/p>\n\n\n\n

Investment Strategy: IP as a Value Signal<\/strong><\/h3>\n\n\n\n

Institutional investors screening biopharma equities should map patent expiration timelines against revenue models for every major product in a company’s portfolio. A stock trading at a premium to sector on peak-sales assumptions may be mispriced if the primary composition-of-matter patent expires within three years of projected commercial peak and the secondary patent estate is thin. Conversely, companies with dense, multi-layer patent estates around their lead products, particularly those with valid formulation and manufacturing patents extending 5 to 8 years beyond the composition date, carry durability that consensus revenue models often undervalue. Watch for companies filing new method-of-use patent applications for new indications of approved products. These filings are leading indicators of indication expansion programs that have not yet entered the clinical trial registry.<\/p>\n\n\n\n

\n\n\n\n

Part 4: White Space Analysis: Finding Uncontested Therapeutic Territory<\/strong><\/h2>\n\n\n\n

White space analysis maps where competitors are not, rather than where they are. The goal is to identify biological targets, patient sub-populations, or therapeutic mechanisms that are scientifically validated but legally uncrowded, creating conditions for a first-mover patent position with durable market exclusivity.<\/p>\n\n\n\n

How to Conduct a Systematic Mechanism-of-Action Landscape<\/strong><\/h3>\n\n\n\n

Start with a defined therapeutic area. Autoimmune disease serves as a useful example because it spans multiple distinct mechanism clusters. Collect all patent applications filed globally in the past 10 years that cover small molecule or biologic interventions targeting any pathway implicated in inflammatory autoimmune pathology. IPC codes provide a coarse initial filter; keywords and classification codes from USPTO and EPO thesauri allow more granular segmentation. Structure the output into mechanism-of-action clusters: TNF-alpha inhibitors, IL-17 pathway, IL-23\/IL-12, JAK-STAT (with sub-segmentation by JAK isoform), S1P receptor modulators, integrin antagonists, BTK inhibitors, and so on.<\/p>\n\n\n\n

The density of patent filings in each cluster reflects commercial competition. TNF-alpha inhibition, dominated by adalimumab (Humira, AbbVie) and its biosimilars, has an extremely dense patent estate with active litigation across dozens of Orange Book-listed patents and BPCIA patent dance proceedings. JAK1-selective inhibition, occupied by filgotinib (Galapagos\/Gilead) and upadacitinib (AbbVie), is less crowded at the composition level but dense at the indication level. What the landscape may reveal, when analyzed at sufficient granularity, is that specific sub-populations, such as seronegative rheumatoid arthritis patients with a defined genetic risk variant, or pediatric populations with refractory juvenile idiopathic arthritis, have very limited patent filings for tailored therapeutic approaches. These are actionable white spaces.<\/p>\n\n\n\n

Target Biology Validation Without the White Space Trap<\/strong><\/h3>\n\n\n\n

The critical question when identifying white space is why it is empty. Two explanations exist. The first is that no one has thought to look there, or that historical technical barriers, such as the difficulty of achieving oral bioavailability for a compound targeting a particular protein family, have only recently been overcome by new chemistry platforms. This is genuine opportunity. The second explanation is that the target has been tried and failed: preclinical data looked promising, multiple companies initiated programs, and all of them encountered a toxicity signal or a pharmacodynamic failure that convinced them the mechanism is not therapeutically tractable in humans.<\/p>\n\n\n\n

Distinguishing between these explanations requires combining patent landscape data with two additional data sets. First, the clinical trial registry (ClinicalTrials.gov and EU Clinical Trials Register): if multiple programs entered Phase 1 or Phase 2 against a target and none progressed, that is a red flag that appears in the trial record even if it does not appear in publications. Second, publication databases: if a target appeared in patent filings 5 to 8 years ago but is now absent from both new filings and recent publications, that silence often reflects the scientific community updating its assessment of the target’s validity.<\/p>\n\n\n\n

Rare Disease as a Structural White Space Opportunity<\/strong><\/h3>\n\n\n\n

Rare diseases, defined in the US as conditions affecting fewer than 200,000 patients, represent a systematic white space category for several structural reasons. Orphan drug designation provides 7 years of market exclusivity in the US (10 years in Europe) that operates independently of and additively with patent protection. Development costs are lower because Phase 3 trials in rare diseases typically require smaller patient populations. Regulatory agencies have dedicated programs (FDA Rare Disease Program, EMA Committee for Orphan Medicinal Products) that provide both scientific advice and accelerated review pathways. The pricing environment reflects the absence of alternatives, enabling revenues that justify the development economics even at small patient population sizes.<\/p>\n\n\n\n

Patent landscape analysis in rare disease categories frequently reveals genuine white space: a genetic disorder with a well-characterized causative mutation, no currently approved therapy, and minimal competing patent activity. When this combination exists, the strategic calculus is clear. A composition-of-matter application filed on a first-in-class therapeutic approach to an unaddressed orphan indication can establish a dominant IP position with years of runway before any competitor emerges.<\/p>\n\n\n\n

Key Takeaways: White Space Analysis<\/strong><\/h3>\n\n\n\n

Systematic mechanism-of-action mapping reveals which therapeutic territories are genuinely uncrowded and which appear uncrowded for negative reasons. The highest-value white spaces are those where recent technical advances have made a previously inaccessible target now druggable, or where patient sub-population stratification has created a distinct commercial opportunity that overlapping broader indication patents do not cover. Rare disease categories are structurally underrepresented in patent filings relative to their commercial potential when orphan regulatory benefits are included in the NPV calculation.<\/p>\n\n\n\n

\n\n\n\n

Part 5: Competitive Landscaping and the 18-Month Intelligence Window<\/strong><\/h2>\n\n\n\n

Patent applications are published 18 months after their priority date in most major jurisdictions. This creates a structured intelligence lag: what a company files today in their laboratory will appear in the public database a year and a half from now. That 18-month window is both a constraint and an opportunity. The constraint is that you cannot see inside a competitor’s current research in real time. The opportunity is that when a filing does appear, it reflects research decisions made 18 months ago, meaning you can infer where that competitor has been deploying resources long before they announce anything publicly.<\/p>\n\n\n\n

Reading a Competitor’s Filing Pattern as a Program Progression Signal<\/strong><\/h3>\n\n\n\n

A single filing tells you that a compound or approach exists. A sequence of filings tells you about program trajectory. The progression from a broad composition-of-matter application to filings covering specific salt forms, crystalline polymorphs, and controlled-release formulations indicates a program moving toward candidate selection and IND submission. The subsequent appearance of clinical-use patents covering specific dosing ranges or patient sub-populations correlates with early human trial data. New combination therapy filings, particularly those naming a specific approved agent as the combination partner, often indicate Phase 2 data suggesting synergy.<\/p>\n\n\n\n

Competitors rarely announce these intermediate steps. They appear in the patent record. A strategy team monitoring a key competitor’s filings in, for example, the GLP-1 receptor agonist space would have seen Novo Nordisk’s semaglutide-related filings accumulate across weight management indications before the Phase 3 SURMOUNT-equivalent data generated headlines. The filing record is the leading indicator.<\/p>\n\n\n\n

The Patent Fence Deconstructed<\/strong><\/h3>\n\n\n\n

Sophisticated originators build what IP attorneys call a ‘patent fence’ or ‘patent thicket’: a dense cluster of granted patents covering the core molecule and its surrounding technology space that makes it difficult for a competitor to sell a similar product without encountering infringement on at least one claim. The structure typically includes the composition-of-matter patent (often expiring first), a family of polymorph patents covering alternative crystalline forms of the API, a set of formulation patents covering the marketed dosage form, one or more process patents covering key manufacturing steps, a group of method-of-use patents covering each approved indication, and additional method-of-use filings covering investigational indications currently in trials.<\/p>\n\n\n\n

AbbVie’s patent strategy around adalimumab (Humira) is the canonical example. The original composition patent expired in the US in 2016. AbbVie had by that time built a fence of over 100 additional patents, many covering formulation, device, and method-of-use aspects of the product, listed in the FDA Orange Book. Biosimilar entrants had to navigate Paragraph IV challenges to each relevant listed patent. The result was that AbbVie maintained US exclusivity until 2023, nearly seven years beyond the original composition expiration, generating additional revenues that have been estimated in excess of $70 billion globally during that extended period.<\/p>\n\n\n\n

Analyzing the structure of this kind of fence in a competitive landscape tells you several things: how long effective exclusivity is likely to persist for the branded product, which specific patents represent the highest-validity barriers (and are therefore most important to analyze for potential challenge), and which aspects of the fence might be weakest (narrow claims, questionable disclosure support) if litigation is a strategic option.<\/p>\n\n\n\n

Commercially Available Intelligence Platforms<\/strong><\/h3>\n\n\n\n

Manual tracking of competitor patent portfolios across the USPTO, EPO, CNIPA, and PCT databases is operationally impractical without technology. Commercial platforms specifically built for pharmaceutical patent intelligence provide curated, structured, and normalized data that makes systematic competitive landscaping feasible.<\/p>\n\n\n\n

DrugPatentWatch, in particular, integrates patent expiration data with FDA Orange Book listings, BPCIA ‘patent dance’ records, exclusivity schedules, and litigation history in a single query environment. For a business development analyst evaluating the competitive dynamics around a specific target, this integration matters: the relevant question is not just ‘what patents exist?’ but ‘which of these patents are Orange Book-listed and therefore create Paragraph IV hatch-waxman exposure for a generic filer?’ That is a legal distinction with direct commercial implications, and platforms that connect those data sets accelerate the analytical process by weeks relative to manual methods.<\/p>\n\n\n\n

Other platforms, including PatSnap, Clarivate Derwent, and Cipher (now Techquity), offer broader cross-industry patent analytics with stronger visualization tools for technology mapping. The choice among platforms depends on whether the primary use case is pharmaceutical-specific (regulatory linkage, Orange Book, BPCIA) versus general competitive intelligence across a broader innovation landscape.<\/p>\n\n\n\n

Key Takeaways: Competitive Landscaping<\/strong><\/h3>\n\n\n\n

Patent filing sequences are a timeline of competitor program investment, visible 18 months after the fact. Analyzing the structure of a competitor’s patent fence, not just its size, reveals the strength of its effective exclusivity and identifies specific legal vulnerabilities. Platforms that integrate patent data with regulatory and litigation records provide the analytical depth needed for commercial decision-making.<\/p>\n\n\n\n

\n\n\n\n

Part 6: Freedom-to-Operate as a Pipeline Gate, Not a Legal Afterthought<\/strong><\/h2>\n\n\n\n

Freedom-to-Operate (FTO) analysis determines whether a specific product, process, or activity can be commercialized without infringing the valid patent rights of a third party. Historically, formal FTO opinions were commissioned from external patent counsel at late-stage development, often just before NDA or BLA submission. That timing is commercially irrational: by Phase 3, a company has committed hundreds of millions of dollars to a program. Discovering a blocking patent at that stage leaves three options, none good: initiate patent litigation from a position of urgency rather than strategy, negotiate a license from a position of extreme dependence, or abandon the program with full write-off.<\/p>\n\n\n\n

Integrating FTO as a Stage-Gate Requirement<\/strong><\/h3>\n\n\n\n

FTO analysis should be a required component of every internal stage-gate review, starting at lead candidate nomination. The question asked at each gate is not ‘will we infringe?’ but ‘has the external patent landscape changed since our last review, and does our current compound structure and proposed clinical indication still have a clear path to commercialization?’<\/p>\n\n\n\n

At lead nomination, the FTO review is necessarily broad. You are assessing whether the target mechanism and general compound class are clear, not whether the specific candidate molecule infringes a specific claim. This is faster and cheaper, and it catches the most dangerous category of error: an entire program direction that is legally encumbered before a single preclinical experiment is run.<\/p>\n\n\n\n

At IND submission, the FTO review becomes more precise. The specific candidate structure is now fixed. The proposed initial indication is defined. The analysis asks whether the compound, at the planned doses and in the planned patient population, would infringe any granted, in-force third-party patent claim. This review should also examine the manufacturing process patents if the synthesis route is proprietary.<\/p>\n\n\n\n

At Phase 2 completion, when the go\/no-go decision for Phase 3 is being made, a full formal FTO opinion from external counsel should be standard. The cost of a comprehensive FTO opinion, typically $50,000 to $150,000 depending on scope, is immaterial relative to the Phase 3 investment it is protecting. Companies that treat this as optional are accepting asymmetric risk.<\/p>\n\n\n\n

Design-Around Strategy: The Value of Early Detection<\/strong><\/h3>\n\n\n\n

When a preliminary FTO review identifies a potentially blocking patent early in discovery, the scientific team retains the flexibility to design around it. Medicinal chemistry can often modify a compound structure, change a stereocentre, alter a substituent pattern, or shift the target binding profile in a way that exits the claims of the blocking patent while preserving pharmacological activity. This design-around option is time-sensitive: it is available when chemists still have broad freedom to explore structure-activity relationships. It is unavailable after a lead candidate has been advanced through IND-enabling studies, enrolled in a Phase 1 trial, and had its formulation locked in.<\/p>\n\n\n\n

The gene therapy field illustrates the stakes. Viral vector delivery systems, particularly adeno-associated virus (AAV) serotype IP, are heavily patented territory. Spark Therapeutics, Voyager Therapeutics, and Regenxbio each hold significant position in specific AAV capsid patents. A developer selecting an AAV serotype for a new gene therapy program without conducting an FTO review of the applicable capsid and manufacturing IP is accepting a serious risk. Early identification of the vector IP landscape allows for capsid selection that either stays within a clearly licensed or public-domain space, or triggers a proactive licensing conversation with the relevant rightholder before the program has clinical sunk costs attached to a specific vector.<\/p>\n\n\n\n

Key Takeaways: FTO Integration<\/strong><\/h3>\n\n\n\n

FTO analysis embedded as a stage-gate requirement transforms IP from a late-stage legal function into an early risk-management tool. The cost of early FTO reviews is orders of magnitude lower than the cost of a late-stage blocking patent discovery. Design-around options and proactive licensing negotiations are only available before structural commitments are made.<\/p>\n\n\n\n

\n\n\n\n

Part 7: Evergreening Roadmaps: The Full Technology Lifecycle Playbook<\/strong><\/h2>\n\n\n\n

‘Evergreening’ describes the practice of securing secondary patents on modifications, improvements, or new applications of an existing drug to extend effective market exclusivity beyond the original composition-of-matter patent expiration. The term is often used pejoratively in policy discussions, but from an IP strategy and commercial perspective, it describes a legitimate and often patient-beneficial approach to lifecycle management. Extended-release formulations improve adherence. Fixed-dose combinations simplify regimens. New indications treat additional patient populations. Each of these is patentable.<\/p>\n\n\n\n

The strategic challenge is anticipating and planning these lifecycle extensions proactively, not reactively, and ensuring that the secondary patent applications are filed with sufficient claim scope and specification support to be commercially meaningful.<\/p>\n\n\n\n

Formulation Technology Roadmap for Small Molecules<\/strong><\/h3>\n\n\n\n

A comprehensive small molecule lifecycle roadmap typically follows this sequence. At the time of NDA approval, the composition-of-matter patent provides primary coverage. Within the first two to three years of commercialization, the company should file patents on the specific approved formulation (tablet matrix, excipient composition, coating system) if not already filed during development. Simultaneously, extended-release versions should be in formulation development, targeting a filing that will be granted and listed in the Orange Book before the composition patent expires.<\/p>\n\n\n\n

The next layer involves patient-segment formulations: pediatric liquids, dispersible tablets for patients with dysphagia, and inhalation formulations where oral systemic delivery creates tolerability issues. These formulations require separate clinical studies (often pediatric studies are mandated by FDA under the Pediatric Research Equity Act) and generate separate IP with independent expiration dates. Finally, fixed-dose combination filings, pairing the drug with a standard-of-care co-medication in the same indication, can extend the franchise into a novel combination product with its own exclusivity period.<\/p>\n\n\n\n

The practical test for whether a secondary patent is commercially valuable is whether it will be listable in the FDA Orange Book. An Orange Book listing means that any Paragraph IV ANDA filer must certify against that patent, triggering a 45-day window for the originator to initiate litigation and an automatic 30-month stay of generic approval. That litigation process, even when ultimately unsuccessful for the originator, delays generic entry and extends the revenue stream. The AbbVie\/Humira patent fence extended US exclusivity by approximately 7 years through exactly this mechanism applied to a biologic context.<\/p>\n\n\n\n

Biologic Lifecycle Extension: The Formulation and Device Layer<\/strong><\/h3>\n\n\n\n

For biologics, the lifecycle management toolkit extends in specific directions that differ from small molecules. The key areas are:<\/p>\n\n\n\n

Drug delivery device patents covering autoinjectors, prefilled syringes, and wearable patch injectors. When a subcutaneous formulation replaces an intravenous infusion, the device-drug combination creates patentable IP that affects the entire patient administration workflow. These patents can be listed in the FDA Purple Book equivalent and can create barriers to biosimilar interchangeability designation even when the molecule itself faces biosimilar competition.<\/p>\n\n\n\n

High-concentration formulation patents for subcutaneous use. Many monoclonal antibodies were originally developed as intravenous infusion products at relatively low concentrations. Developing a stable high-concentration formulation that allows subcutaneous self-administration by the patient involves significant formulation chemistry (viscosity reduction, aggregation prevention, excipient optimization) and generates patentable inventions. The resulting subcutaneous formulation can be protected by patents that extend well beyond the composition-of-matter expiration.<\/p>\n\n\n\n

Combination therapy patents. As clinical evidence accumulates showing synergistic efficacy of the biologic with a small molecule partner, the company can file patents on the specific combination therapy, including the specific dosing schedule and patient selection criteria. These combination patents create a layer of protection for the commercial strategy built around the combination even after the individual components have lost exclusivity.<\/p>\n\n\n\n

Indication Expansion Patent Strategy<\/strong><\/h3>\n\n\n\n

Each new indication approved for a drug can, in principle, be covered by a new method-of-use patent. The strategic value of these patents depends on whether the new indication has sufficiently distinct IP. A drug approved initially for moderate-to-severe plaque psoriasis being approved for psoriatic arthritis may face arguments that the method-of-use is obvious in light of the shared underlying immunological mechanism. A drug approved for an oncology indication being developed for a non-oncology fibrotic disease presents a more novel method-of-use that has a stronger basis for patentability.<\/p>\n\n\n\n

The most commercially valuable indication expansion patents are those that (1) cover a large patient population with high unmet need, (2) are not obvious from the original indication’s biological mechanism, and (3) are filed with claim scope broad enough to cover the standard clinical protocol but narrow enough to be well-supported by the data in the specification. The intersection of these three criteria requires close collaboration between the clinical team generating the data and the patent attorneys drafting the application.<\/p>\n\n\n\n

Key Takeaways: Evergreening Roadmaps<\/strong><\/h3>\n\n\n\n

Lifecycle management through secondary patents is a planned, multi-year process that should begin before launch, not after peak sales. The commercially meaningful test for a secondary patent in the US context is whether it meets the criteria for Orange Book or Purple Book listing, which determines whether it creates a Paragraph IV\/BPCIA challenge obligation for generic and biosimilar filers. Biologic lifecycle strategy specifically prioritizes high-concentration subcutaneous formulation patents, delivery device patents, and combination therapy method-of-use patents as the layers most likely to create durable exclusivity beyond the composition patent expiration.<\/p>\n\n\n\n

\n\n\n\n

Part 8: Biosimilar IP Defense: Manufacturing Patents as the Last Fortress<\/strong><\/h2>\n\n\n\n

The 12-year BPCIA exclusivity period for biologics is well-understood. What is less appreciated in commercial strategy discussions is how the manufacturing patent estate, not the composition-of-matter patent, has become the primary tool for extending biologic market exclusivity into the post-exclusivity period.<\/p>\n\n\n\n

The ‘Process Is the Product’ Doctrine in Practice<\/strong><\/h3>\n\n\n\n

Biologic manufacturing involves an upstream bioprocess (cell line development, culture media composition, feeding strategy, bioreactor conditions), a downstream purification process (chromatography sequence, viral inactivation steps, ultrafiltration\/diafiltration parameters), and a formulation and fill-finish process (buffer composition, protein concentration, stabilizer excipients). Each step produces a distinctive molecular fingerprint in the final drug product: glycosylation patterns, charge heterogeneity, aggregation profile, and post-translational modification distribution.<\/p>\n\n\n\n

FDA’s approach to biosimilarity requires that a proposed biosimilar demonstrate ‘no clinically meaningful differences’ from the reference product in terms of safety, purity, and potency. This assessment is heavily dependent on analytical data showing molecular similarity in the attributes produced by the manufacturing process. Demonstrating biosimilarity when the manufacturing process is substantially different is analytically harder and regulatory pathway more uncertain.<\/p>\n\n\n\n

An originator with a dense manufacturing patent estate forces biosimilar developers into a difficult position. The developer cannot copy the reference product’s manufacturing process without infringing those patents. Designing an independent process produces a molecule that may be analytically similar but may also have detectable differences in glycosylation or aggregation that complicate biosimilarity demonstration. Each deviation from the reference process is a point where the biosimilar developer must generate additional analytical and clinical bridging data.<\/p>\n\n\n\n

The BPCIA Patent Dance: Strategic Use of Information Exchange<\/strong><\/h3>\n\n\n\n

The Biologics Price Competition and Innovation Act established a structured information exchange process, colloquially called the ‘patent dance,’ between a biosimilar applicant and the reference product sponsor. The biosimilar applicant provides its abbreviated BLA to the originator. The originator responds with a list of patents it believes would be infringed. The parties then negotiate which patents will be litigated in the first wave and which are deferred.<\/p>\n\n\n\n

From the originator’s perspective, the patent dance is an opportunity to deploy the full breadth of the manufacturing patent estate strategically. By listing a large number of manufacturing process patents in the initial exchange, the originator forces the biosimilar developer into a complex litigation environment that requires resources and time to resolve. Small biosimilar developers with limited litigation budgets may find the scope of the patent list prohibitive. Larger biosimilar developers, including Sandoz, Celltrion, Boehringer Ingelheim Biopharmaceuticals, and Samsung Bioepis, have the financial capacity to litigate across multiple patent families simultaneously and have demonstrated this capacity against AbbVie, Amgen, and Genentech.<\/p>\n\n\n\n

For originator strategy teams, the practical implication is that manufacturing patents must be filed with this eventual patent dance in mind. Each patent in the manufacturing estate needs to be broad enough to cover meaningful commercial embodiments of the biosimilar’s likely process choices, not just the originator’s current process. That requires prospective claim drafting that anticipates the range of alternative manufacturing approaches a biosimilar developer might use.<\/p>\n\n\n\n

Interchangeability Designation and Its IP Implications<\/strong><\/h3>\n\n\n\n

FDA’s biosimilar approval pathway allows, but does not require, an applicant to seek an ‘interchangeability’ designation. An interchangeable biosimilar can be substituted for the reference product at the pharmacy level without prescriber intervention, the same way a generic small molecule is dispensed. Achieving interchangeability requires a switching study demonstrating that patients alternating between the biosimilar and the reference product experience no greater risk than patients who remain on the reference product throughout.<\/p>\n\n\n\n

The first interchangeable biosimilar to be approved for a given reference product receives a period of exclusivity for interchangeability designation, during which FDA will not approve another biosimilar as interchangeable for the same reference product. This exclusivity period is separate from patent protection but interacts with it commercially. For originators, the interchangeability designation of a biosimilar is the most commercially significant biosimilar regulatory event because it is the step that enables pharmacy-level substitution and drives the rapid volume share erosion seen with small molecule generics.<\/p>\n\n\n\n

The patent strategy implication is that originators should monitor biosimilar applications that include switching study designs, as these signal an intent to seek interchangeability designation. Knowing which biosimilar competitor is furthest down the path to interchangeability allows the originator to prioritize which manufacturing process patents to actively assert in litigation.<\/p>\n\n\n\n

Key Takeaways: Biosimilar IP Defense<\/strong><\/h3>\n\n\n\n

Manufacturing process patents are the primary commercial defense for biologics in the post-BPCIA exclusivity period. A dense manufacturing patent estate, drafted with prospective awareness of the biosimilar development alternatives a competitor is likely to use, forces biosimilar entrants into complex multi-patent litigation and increases the analytical burden of their biosimilarity demonstration. Understanding the BPCIA patent dance mechanics allows originators to use the information exchange process strategically rather than treating it as a compliance obligation.<\/p>\n\n\n\n

\n\n\n\n

Part 9: Paragraph IV Litigation Strategy and Orange Book Dynamics<\/strong><\/h2>\n\n\n\n

The Hatch-Waxman Act established the Paragraph IV certification mechanism as the primary pathway for generic small molecule market entry. An ANDA filer that certifies, under Paragraph IV, that a patent listed in the Orange Book is invalid, unenforceable, or will not be infringed by the generic product triggers a 45-day window for the originator to file a patent infringement suit. If suit is filed, an automatic 30-month stay prevents FDA from approving the ANDA until either the stay expires or the litigation is resolved, whichever comes first.<\/p>\n\n\n\n

The First Filer Advantage and Shared Exclusivity<\/strong><\/h3>\n\n\n\n

The first ANDA applicant to file a Paragraph IV certification against a given Orange Book patent is entitled to 180 days of generic market exclusivity from the date of first commercial marketing. This exclusivity is shared among all applicants who file on the same day as the first filer. The commercial value of this 180-day window is substantial: during the exclusivity period, the first-wave generic typically prices at 30% to 50% below the branded price while capturing 70% to 90% of prescription volume. Subsequent generic entrants, entering after the 180-day period with additional competing generics, face rapid price erosion.<\/p>\n\n\n\n

For originator strategy teams, understanding which generic filers are approaching the market matters because it informs the litigation triage decision. Not all Orange Book-listed patents are equal in commercial importance. A process patent with narrow claims covering a specific crystallization technique that a generic can easily design around is not worth defending with the same resources as a formulation patent covering the precise extended-release matrix used in the marketed product. Patent counsel and commercial strategy need to align on which patents in the Orange Book estate represent genuine barriers and which are primarily signal rather than substance.<\/p>\n\n\n\n

Citizen Petitions and Pre-Approval FDA Interactions<\/strong><\/h3>\n\n\n\n

Originators sometimes file citizen petitions with FDA challenging the adequacy of a generic or biosimilar applicant’s data package. When timed strategically, a citizen petition can delay FDA’s review while the originator prepares litigation or completes additional patent filings. FDA has become increasingly skeptical of citizen petitions filed immediately before an anticipated generic approval, and the agency has authority under FDAAA to deny petitions filed primarily for delay. The FDA Citizen Petition process is therefore a tactical tool with limited strategic half-life, not a reliable independent mechanism for extending exclusivity.<\/p>\n\n\n\n

At-Risk Generic Launch: When Patent Uncertainty Meets Commercial Pressure<\/strong><\/h3>\n\n\n\n

Generic companies sometimes launch their product ‘at risk’ after receiving FDA approval before patent litigation is resolved. This occurs when the generic filer believes the remaining Orange Book patents are invalid or narrowly scoped but has not yet obtained a court ruling. The risk is that if the originator ultimately prevails in litigation, the generic company is liable for the originator’s lost profits during the at-risk period. For high-revenue products, this exposure can be substantial.<\/p>\n\n\n\n

From the originator’s perspective, an at-risk launch by a generic competitor changes the commercial calculus immediately. The pricing umbrella is compressed. Managed care contracts come under pressure. The originator must decide whether to pursue injunctive relief, which requires demonstrating a likelihood of success on the merits and irreparable harm, or to focus resources on the damages case at trial. Monitoring the patent litigation docket for indications that a generic filer may be preparing an at-risk launch is therefore a critical commercial intelligence function for any product approaching patent expiry.<\/p>\n\n\n\n

Key Takeaways: Paragraph IV and Orange Book Strategy<\/strong><\/h3>\n\n\n\n

Orange Book listing decisions for secondary patents should be made with litigation defensibility as the primary criterion, not portfolio completeness. The 30-month automatic stay is the commercial mechanism that justifies investing in Orange Book-eligible patent prosecution. Understanding the first-filer 180-day exclusivity dynamic matters for competitive timing: the entry of the first generic defines the revenue cliff trajectory.<\/p>\n\n\n\n

\n\n\n\n

Part 10: Using Patent Intelligence to Win High-Value Partnerships and Deals<\/strong><\/h2>\n\n\n\n

For biotech companies operating before profitability, the partnership transaction is the primary mechanism for accessing the capital and commercial infrastructure needed to bring a program to market. The deal architecture, including upfront payments, milestone structures, royalty rates, and co-commercialization rights, is shaped above all else by two factors: clinical data quality and IP position. Clinical data is visible to both parties through trial readouts. IP position requires active construction and communication.<\/p>\n\n\n\n

The IP Deck: What a BD&L Team Looks For First<\/strong><\/h3>\n\n\n\n

An experienced BD&L team at a large pharmaceutical company evaluates an asset by asking a specific sequence of questions about its patent estate. First, is the composition-of-matter patent granted, or still pending? A pending application with broad claims is valuable but uncertain; a granted composition patent with a clear file history and no pending re-examinations is a firm foundation. Second, what is the patent family footprint? Coverage in the US, Europe, Japan, China, and at least the major emerging markets is expected for any asset with global commercial ambitions. Third, what is the effective exclusivity runway from projected approval date to the earliest expected generic or biosimilar entry under realistic litigation assumptions? A product with 15 years of post-launch exclusivity is dramatically more valuable than one with 6 years, all else equal. Fourth, are there secondary patents that extend the commercial franchise beyond the composition expiration? A layered estate indicates strategic IP management and a company that has thought beyond the initial approval.<\/p>\n\n\n\n

A company that can walk a potential partner through all four of these questions with a clear, organized, data-supported answer is in a fundamentally different negotiating position than one that presents a patent estate as a list of application numbers and filing dates.<\/p>\n\n\n\n

IP Strength as a Royalty Rate Driver<\/strong><\/h3>\n\n\n\n

Royalty rates in pharmaceutical licensing deals are a direct function of perceived IP durability. Industry benchmark data compiled from published deal disclosures and licensing databases suggest the following ranges. A first-in-class biologic with a granted composition-of-matter patent, a layered secondary estate, and phase 2 proof-of-concept data in a large indication typically commands royalties of 10% to 18% of net sales in a major licensing transaction. A fast-follower small molecule with method-of-use protection only and an exposed near-term composition expiration may generate royalties of 4% to 8%. The difference, applied to projected peak sales of $1 billion, is $60 million to $140 million per year in royalty income. Over the life of the royalty period, this gap is the economic expression of IP quality.<\/p>\n\n\n\n

Upfront payments follow the same logic. They represent the partner’s assessment of the probability-weighted NPV of the deal, de-risked by IP strength. An asset with defensible composition coverage and 12 years of post-launch exclusivity has lower NPV variance than one with weak IP and uncertain entry timing. Lower variance justifies higher upfront commitments because the partner has greater confidence that their investment will generate the modeled return.<\/p>\n\n\n\n

Crafting a Patent Narrative for a Partnering Presentation<\/strong><\/h3>\n\n\n\n

A patent landscape visualization in a partnering deck does several things simultaneously. It demonstrates the white space where the company’s asset operates, showing that the mechanism of action is not overcrowded by competitors who would rapidly commoditize the market after any co-development deal. It shows the secondary patent estate layered against a commercial timeline, making the durability of the franchise visible rather than abstract. It maps the global filing footprint against the partner’s commercial geography, demonstrating alignment with the partner’s market priorities.<\/p>\n\n\n\n

This visual story is more persuasive than text assertions about differentiation because it is built from public data that the partner’s own IP team can independently verify. When the partner runs their own landscape analysis and reaches the same conclusions, it builds confidence rather than requiring them to simply accept the seller’s characterization.<\/p>\n\n\n\n

Key Takeaways: Deal-Driven IP Strategy<\/strong><\/h3>\n\n\n\n

Patent strength directly translates into deal economics through royalty rates, upfront payments, and milestone structure. IP position is most effectively communicated in a partnering context through a visual patent narrative, not a document inventory. The gap in deal economics between a well-constructed patent estate and a weak one is large enough that IP strategy investment pays for itself many times over in any transaction of meaningful scale.<\/p>\n\n\n\n

Investment Strategy: Reading Patent Filings as BD&L Signals<\/strong><\/h3>\n\n\n\n

Institutional investors and hedge funds analyzing biotech equities should treat patent filing activity as a forward-looking indicator of partnering intent. A small-cap biotech that files an accelerated series of national phase applications across major jurisdictions, expands its secondary patent families, and initiates Orange Book pre-submission consultations with FDA is signaling preparedness for a licensing transaction or acquisition process. These signals often precede deal announcements by 6 to 18 months. Patent activity monitoring using DrugPatentWatch or equivalent platforms gives investors access to this signal stream before it is priced into the equity.<\/p>\n\n\n\n

\n\n\n\n

Part 11: IP Due Diligence: The Two-Way Street That Shapes Deal Terms<\/strong><\/h2>\n\n\n\n

IP due diligence in a pharmaceutical deal is a structured forensic examination of an asset’s patent estate conducted by the potential partner’s IP counsel, technical experts, and commercial strategy team. It is the process through which the assertions made during business development discussions are tested against primary sources. The outcome either validates the deal rationale or identifies issues that change the terms, require remediation, or kill the deal.<\/p>\n\n\n\n

What Gets Scrutinized in IP Due Diligence<\/strong><\/h3>\n\n\n\n

Chain of title is the first check. The patent must be properly assigned from each named inventor to the company. If the drug was discovered at a university and licensed to the company, the license agreement and any sublicense rights must be examined. If any inventor is no longer with the organization, their assignment document must be confirmed. A cloud on title, such as an inventor who signed an assignment under circumstances that can be challenged, or a license agreement with a field-of-use restriction that limits what the company can grant to the partner, is a material issue that must be resolved before or during the transaction.<\/p>\n\n\n\n

Patent validity is the second examination. The partner’s IP team will conduct an independent prior art search to assess whether the patents in the estate would survive an inter partes review (IPR) challenge at the Patent Trial and Appeal Board (PTAB) or an opposition at the EPO. PTAB institution rates for petitions challenging pharmaceutical patents have historically run at approximately 60%, meaning that the majority of challenged patents face substantive review. If the partner’s IP team assesses a composition-of-matter patent as having elevated IPR vulnerability, the deal terms will reflect that uncertainty through reduced upfront or milestone payments, or through representations and warranties that shift risk to the licensor.<\/p>\n\n\n\n

The file history of a patent, the record of correspondence between the applicant and the patent office during prosecution, can create arguments against the patent owner through the doctrine of prosecution history estoppel. If the applicant argued during prosecution that the invention was distinct from a specific prior art reference by adding a claim limitation, that argument can later be used by an infringer to argue that the claim does not cover embodiments similar to the prior art. Partners look for prosecution histories that contain limiting arguments or claim amendments that narrow the original claim scope.<\/p>\n\n\n\n

FTO from the licensor’s perspective is also examined. Has the company conducted an FTO analysis for its own product? Are there third-party patents that the product might infringe? The partner wants to know about these potential liabilities before they assume co-development risk.<\/p>\n\n\n\n

Reverse Due Diligence: Analyzing the Partner’s Portfolio<\/strong><\/h3>\n\n\n\n

The smaller biotech conducting its own reverse diligence on a potential large pharma partner should focus on specific questions. Does the partner hold patents in the same mechanism or indication space that could conflict with or compete with the in-licensed asset? A large pharma partner that holds a dominant position in TNF-alpha inhibition and is in-licensing an IL-17 inhibitor asset may face internal cannibalization incentives that reduce their motivation to aggressively develop and commercialize the in-licensed product. Examining the partner’s patent estate in the relevant therapeutic area reveals whether the deal is additive or potentially conflicting with their internal pipeline.<\/p>\n\n\n\n

The partner’s patent litigation history is another relevant data set. A company with a pattern of asserting weak patents aggressively against competitors, or of using its patent estate to suppress competitive development rather than to advance it commercially, is a different kind of partner than one whose litigation history is primarily defensive. This history is public record in the federal court system and is accessible through litigation database services.<\/p>\n\n\n\n

Key Takeaways: IP Due Diligence<\/strong><\/h3>\n\n\n\n

IP due diligence is most efficiently navigated when the company under examination has maintained organized, complete IP records from the beginning. Title chains, inventor assignments, file histories, FTO analyses, and licensing agreements should be maintained in a state that allows rapid assembly of a due diligence data room. Companies that have done this work in advance signal operational quality to the partner and reduce the time-to-close by weeks.<\/p>\n\n\n\n

\n\n\n\n

Part 12: Building the Internal Patent Intelligence Function<\/strong><\/h2>\n\n\n\n

Embedding patent intelligence into corporate strategy requires more than purchasing a database subscription. It requires building a cross-functional function with the right skills, the right analytical processes, and the right organizational positioning to ensure that IP insights reach decision-makers before decisions are made, not after.<\/p>\n\n\n\n

The Hybrid Team Model<\/strong><\/h3>\n\n\n\n

The team that generates actionable patent intelligence is not composed entirely of patent attorneys. Patent attorneys are essential for formal opinions and prosecution strategy, but the day-to-day analytical work requires a combination of skills that patent law training does not typically develop.<\/p>\n\n\n\n

A patent analyst or scientist, with a doctoral degree in biology, chemistry, or pharmacology combined with training in patent analysis, reads technical patent content and translates it into scientific and competitive language that strategy teams can use. This person bridges the lab and the legal department.<\/p>\n\n\n\n

A data scientist or bioinformatician manages the technical infrastructure: database queries, natural language processing pipelines for large-scale patent classification, and visualization tools for landscape mapping. As the volume of relevant patent filings grows globally, particularly from China and Korea, processing this volume accurately without computational support is not feasible.<\/p>\n\n\n\n

A business or commercial analyst connects patent data to market models. Their job is to answer the ‘so what?’ question for each finding: if this competitor’s Phase 2 program is advancing as the patent record suggests, what does that do to our projected market share in year 5? This person also owns the integration between patent expiration timelines and revenue forecasting models.<\/p>\n\n\n\n

The function should report directly to the Chief Strategy Officer or Head of Business Development, not exclusively to the General Counsel. Organizational positioning determines whether patent intelligence is consulted at strategy-setting moments or only at legal risk-assessment moments. The difference in impact is substantial.<\/p>\n\n\n\n

Technology Infrastructure for Patent Intelligence<\/strong><\/h3>\n\n\n\n

At the foundational level, a subscription to DrugPatentWatch or an equivalent pharmaceutical-specific platform provides access to curated patent-regulatory-litigation integrated data sets. At the next level, general patent analytics platforms (PatSnap, Clarivate Derwent Innovation, Cipher) add broader technology mapping capability and tools for semantic search and visualization.<\/p>\n\n\n\n

The emerging layer is AI-powered patent analysis. Large language models can now be applied to patent corpus classification, claim scope assessment, and identifying semantic relationships between patents across different technology areas that share relevant claims. Several startups, including Patlytics, Anaqua, and Specifio, offer AI-powered tools for specific patent workflows including claim drafting, prior art search, and validity assessment. These tools accelerate analytical processes that previously required weeks of attorney time, bringing the iteration speed of patent landscape work closer to the speed of business strategy decisions.<\/p>\n\n\n\n

The integration goal, which is achievable with current technology, is a single analytical environment where a strategist can query a specific drug target and retrieve, in a single view: all relevant patent filings and their current status, clinical trial registrations and their current phase, published scientific literature, FDA regulatory filings, and market sales data where available. This integrated view eliminates the data-silo problem that currently forces analysts to manually correlate information from five or six separate platforms before reaching a conclusion.<\/p>\n\n\n\n

Key Takeaways: Building the Patent Intelligence Function<\/strong><\/h3>\n\n\n\n

Patent intelligence generates strategic value only when organized as a continuous, cross-functional process with clear organizational positioning relative to business development and strategy decisions. The technical infrastructure to support this function is available today. The organizational design question, specifically where the function sits and who it reports to, determines whether the output influences decisions or files in a legal department report.<\/p>\n\n\n\n

\n\n\n\n

Part 13: AI, Predictive Analytics, and the Next Generation of IP Strategy<\/strong><\/h2>\n\n\n\n

Artificial intelligence is changing patent analysis at multiple levels simultaneously. Understanding these changes is important both for the near-term decisions about tool adoption and for the longer-term strategic question of how AI-generated inventions will be protected and valued.<\/p>\n\n\n\n

AI-Powered Patent Classification and Landscape Analysis<\/strong><\/h3>\n\n\n\n

The basic task of classifying patents by technology area, therapeutic mechanism, and biological target has historically required manual expert review. AI-powered classification using fine-tuned language models now performs this task at the scale of the entire global pharmaceutical patent database with classification accuracy that, for well-defined categories, exceeds 90%. This makes comprehensive landscape analyses that previously required months of attorney and analyst time achievable in days.<\/p>\n\n\n\n

More sophisticated applications include semantic clustering, which groups patents by the underlying biological concepts they address rather than by explicit keyword matches. This matters because patent applicants use varied language, and a landscape based on keyword search misses a significant fraction of relevant documents. Semantic clustering based on embedding representations of patent texts captures synonymous descriptions and related concepts that keyword search would miss.<\/p>\n\n\n\n

Predictive Modeling for Clinical and Commercial Outcomes<\/strong><\/h3>\n\n\n\n

Integrating patent filing patterns with clinical trial outcome data creates the basis for predictive models that forecast program success probabilities. The observation that specific patterns of patent activity, such as a rapid series of formulation and manufacturing filings following a composition application, correlate with subsequent Phase 2 trial initiation has been validated in several academic studies. Training a machine learning model on this pattern, combined with target biology characteristics and mechanism of action classification, produces a program success probability estimate that supplements, without replacing, expert scientific judgment.<\/p>\n\n\n\n

For portfolio managers, this kind of model output provides a data-anchored second opinion on program risk assessments. When the model’s success probability for a program significantly diverges from the internal team’s assessment, that divergence is a prompt for deeper review, not an automatic override of the internal view.<\/p>\n\n\n\n

The AI Inventor Question and Its Patent Strategy Implications<\/strong><\/h3>\n\n\n\n

Courts and patent offices in major jurisdictions have consistently held that an AI system cannot be listed as an inventor on a patent application. The Federal Circuit’s 2022 decision in Thaler v. Vidal confirmed this for US patents. EPO’s position is the same. The practical implication for companies using AI systems to generate drug candidate structures, as Exscientia, Insilico Medicine, Relay Therapeutics, and others are doing, is that the human scientists directing and interpreting the AI output must be named as the inventors, and the inventorship narrative must document the human creative contribution that meets the legal standard for inventorship.<\/p>\n\n\n\n

This creates an IP documentation challenge that is currently unsolved for many AI-driven discovery companies. If an AI system generates a molecular structure that is then synthesized and validated by a scientist who made no creative contribution to the molecular design, the inventorship of that composition-of-matter patent is legally uncertain. Companies at the frontier of AI-driven drug discovery are working with specialized IP counsel to develop inventorship frameworks that satisfy current legal requirements while accurately reflecting the nature of the discovery process. This is an area where the law will continue to evolve, and companies with large AI-generated discovery pipelines need to monitor legislative and regulatory developments closely.<\/p>\n\n\n\n

Key Takeaways: AI and Future Patent Strategy<\/strong><\/h3>\n\n\n\n

AI-powered tools are available now and provide immediate analytical efficiency gains in patent classification, landscape analysis, and prior art search. Predictive modeling integrating patent and clinical data is an emerging capability with practical portfolio management applications. The inventorship question for AI-generated compounds is a current legal uncertainty that requires proactive management by companies using AI discovery platforms.<\/p>\n\n\n\n

\n\n\n\n

Part 14: Digital Therapeutics and the New Frontier of SaMD Patenting<\/strong><\/h2>\n\n\n\n

Software as a Medical Device (SaMD) and digital therapeutics (DTx) represent a category of therapeutic intervention that the patent system was not originally designed to accommodate. The leading DTx companies, including Pear Therapeutics (now in bankruptcy but with IP assets that remain commercially relevant), Akili Interactive, and Freespira, have developed software-based interventions for substance use disorder, ADHD, and PTSD, respectively, that FDA has cleared as medical devices. The patent strategy for these products combines elements of software patenting, medical device patenting, and pharmaceutical method-of-use patenting in ways that are still being established.<\/p>\n\n\n\n

What Can Be Patented in the DTx Space<\/strong><\/h3>\n\n\n\n

Software algorithms executed to generate a therapeutic output can be patented when they are implemented in a specific, non-abstract way and produce a specific technical result. The Supreme Court’s Alice\/Mayo framework restricts the patentability of abstract software concepts, but a specific algorithm that uses a defined set of user behavioral data inputs to generate a cognitive behavioral therapy intervention protocol with clinical evidence of efficacy in a defined patient population is likely patent-eligible as a specific technical implementation. The key is drafting claims that tie the software process to the specific technical result and its clinical application, not to the abstract idea of ‘using software to deliver therapy.’<\/p>\n\n\n\n

Sensor and data acquisition claims cover the hardware and software systems used to measure patient state variables, whether physiological (heart rate variability, sleep architecture, galvanic skin response) or behavioral (response time, error rate, engagement duration). These measurement systems, when novel, are patentable as device inventions.<\/p>\n\n\n\n

The user interface and interaction design of a DTx, while not typically patentable as a design patent in a clinically meaningful sense, can contribute to de facto exclusivity through network effects, data accumulation, and regulatory lock-in: once a DTx has a cleared indication, its specific clinical protocol and data package are the baseline that a competitor must surpass, creating an evidence barrier that functions like IP protection even when formal patent coverage is narrow.<\/p>\n\n\n\n

Key Takeaways: DTx Patent Strategy<\/strong><\/h3>\n\n\n\n

Companies developing digital therapeutics need patent strategy that addresses algorithm, device, method-of-use, and data claims simultaneously. The field is early enough that establishing a foundational composition-of-process equivalent position, covering the specific software-sensor-behavioral intervention combination, is achievable for first movers. As FDA’s DTx regulatory framework continues to develop under the Software Pre-Certification program and related initiatives, the evidentiary standard for clearance is also the de facto competitive moat.<\/p>\n\n\n\n

\n\n\n\n

Part 15: China’s Patent Surge and Its Implications for Global Filing Strategy<\/strong><\/h2>\n\n\n\n

China’s pharmaceutical patent filing volume has grown at compound annual rates exceeding 15% over the past decade, and CNIPA has become the second-largest national patent office by filing volume. More importantly for competitive intelligence purposes, Chinese biopharma companies, including BeiGene, Zymeworks, Legend Biotech, and Innovent Biologics, are no longer filing primarily defensive or follow-on IP. They are filing composition-of-matter patents on novel mechanisms and structures that, in some therapeutic areas, represent genuine first-in-class inventions.<\/p>\n\n\n\n

CNIPA Data Integration in Competitive Landscapes<\/strong><\/h3>\n\n\n\n

Most pharmaceutical competitive landscapes built on Western patent databases systematically undercount Chinese patent activity because CNIPA filings are in Chinese, indexed under a separate classification system, and processed through different natural language processing pipelines than English-language databases. A competitive landscape that does not include CNIPA-sourced data for any therapeutic area where Chinese companies are active is missing a material fraction of the relevant patent activity.<\/p>\n\n\n\n

The practical integration challenge is linguistic and technical. Machine translation quality for Chinese patent documents has improved substantially with current large language model capabilities, but translation errors remain higher for chemical structure descriptions and technical claim language than for standard prose. Specialized services that combine computational translation with expert review are the current standard for high-stakes landscape analyses covering CNIPA documents.<\/p>\n\n\n\n

Filing in China as a Strategic Requirement<\/strong><\/h3>\n\n\n\n

The Chinese pharmaceutical market is the second-largest globally by revenue and growing. Any biopharmaceutical product with global commercial ambitions needs patent protection in China. CNIPA prosecution has specific procedural characteristics that differ from USPTO and EPO practice, including different standards for what constitutes sufficient disclosure to support broad claims, a different approach to claim amendment during prosecution, and a bifurcated system where patent validity and infringement are handled by separate authorities (CNIPA for invalidation, courts for infringement). Companies that have not developed Chinese filing and prosecution expertise, either in-house or through a Chinese IP firm relationship, are accepting unnecessary IP risk in one of the industry’s most important markets.<\/p>\n\n\n\n

Chinese pharmaceutical companies filing Paragraph IV-equivalent challenges in the US, Europe, and other markets is an emerging trend. BeiGene’s US commercial operations in oncology and Zymeworks’ partnership structures with US companies mean that Chinese-originated IP is increasingly appearing in the same competitive landscapes as Western-originated IP. A global IP strategy that treats Chinese filings as peripheral rather than central is no longer adequate.<\/p>\n\n\n\n

Key Takeaways: China Patent Strategy<\/strong><\/h3>\n\n\n\n

CNIPA filings must be integrated into competitive landscapes for any therapeutic area where Chinese companies are active. Failing to file in China means forfeiting market protection in the second-largest pharmaceutical market. Understanding CNIPA-specific prosecution standards and enforcement mechanisms is necessary for companies with Chinese commercial ambitions. Chinese companies’ emergence as genuine innovators, not just generic manufacturers, changes the competitive patent dynamics in multiple therapeutic areas simultaneously.<\/p>\n\n\n\n

\n\n\n\n

Consolidated Key Takeaways<\/strong><\/h2>\n\n\n\n

Across the sections above, several organizing principles emerge for IP teams, portfolio managers, and senior decision-makers.<\/p>\n\n\n\n

Patent data is best understood as a continuous intelligence stream, not a static legal record. When monitored systematically, it reveals competitor research priorities 18 months before public disclosure, program advancement signals embedded in sequential filing patterns, and geographic commercial strategy legible from national phase entry decisions.<\/p>\n\n\n\n

IP valuation anchored in patent-adjusted NPV calculations, accounting for effective exclusivity runway and litigation probability scenarios, produces better portfolio prioritization decisions than cost-basis or qualitative assessments of IP strength.<\/p>\n\n\n\n

FTO analysis integrated at each stage gate converts a legal risk assessment into a pipeline de-risking tool. Early identification of blocking patents preserves design-around flexibility that is unavailable once clinical development locks in a compound structure.<\/p>\n\n\n\n

Secondary patent estates, including formulation, manufacturing process, combination therapy, and indication expansion patents, are the primary mechanism for extending effective market exclusivity beyond composition-of-matter expiration. Planning this multi-layer estate should begin before first approval, not after peak sales.<\/p>\n\n\n\n

For biologics specifically, manufacturing process patents have become the most commercially important defense layer against biosimilar competition in the post-BPCIA exclusivity period.<\/p>\n\n\n\n

IP strength directly drives deal economics. Royalty rate differentials between strong and weak patent estates, applied to major product revenues, generate NPV differences that dwarf the cost of building and maintaining a strong IP function.<\/p>\n\n\n\n

Cross-functional IP intelligence, positioned organizationally to inform strategy and business development decisions rather than exclusively serving legal compliance, generates the highest return on patent investment.<\/p>\n\n\n\n

\n\n\n\n

Investment Strategy Section: Pharma\/Biotech Equity and Deal Analysis<\/strong><\/h2>\n\n\n\n

Patent intelligence inputs are material to equity valuation in biopharma but are rarely incorporated systematically into consensus research. The following frameworks apply patent analysis to investment decisions.<\/p>\n\n\n\n

For long-position screening, identify companies with composition-of-matter patent coverage extending at least 8 years beyond their lead product’s projected approval date and at least one layer of secondary patent protection filed in the past 3 years. Add a filter for companies with indication expansion clinical programs in additional patent-protected territory. These companies have revenue visibility that consensus models typically undervalue because the market tends to apply generic discount rates to the entire post-peak sales period without differentiating between protected and exposed years.<\/p>\n\n\n\n

For short-position or risk screening, identify companies where the primary composition-of-matter patent expires within 3 years of projected commercial peak sales and where the secondary patent estate is thin (fewer than 5 Orange Book-listed patents for small molecules, no credible high-concentration subcutaneous formulation or device patent for biologics). Overlay any active Paragraph IV certifications that have been filed by generic challengers: an at-risk generic launch scenario priced as a tail risk in consensus models can be a front-loaded risk when the patent litigation record is examined carefully.<\/p>\n\n\n\n

For M&A and deal event analysis, patent filing activity is a leading indicator of transaction preparedness. Accelerated national phase filings, new Orange Book submissions, and BD&L conference activity patterns, trackable through conference registration databases and patent filing timestamps, frequently precede deal announcements by 6 to 18 months. These signals, accessible through specialized patent intelligence platforms, give sophisticated investors access to a data source that is material to deal probability assessment and is not reflected in consensus estimates.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q: How should a small biotech with limited budget prioritize patent intelligence investment?<\/strong><\/p>\n\n\n\n

Start with a targeted subscription to a pharmaceutical-specific patent platform that integrates regulatory data. Focus the monitoring scope on your specific therapeutic area and your direct competitive set, not the entire pharmaceutical patent universe. Designate one scientifically trained person as the primary patent analyst and build systematic landscape review into each stage-gate process. The cost of a targeted monitoring system is well below $50,000 annually. The cost of a Phase 3 program failure attributable to an identified blocking patent that was never analyzed is measured in hundreds of millions.<\/p>\n\n\n\n

Q: How do you distinguish genuine white space from abandoned territory?<\/strong><\/p>\n\n\n\n

Cross-reference the patent landscape with clinical trial registrations for the same mechanism. If patents were filed 5 to 8 years ago but no clinical trial for that mechanism appears in the registry, investigate whether the programs failed in preclinical development by reviewing relevant publications and conference proceedings. White space that coincides with silent clinical trial registers and a gap in recent scientific publications is more likely to be a scientific failure zone than unclaimed opportunity. White space in a scientifically active target area where new publications are appearing but patent filings are sparse is more likely to represent a genuine opportunity.<\/p>\n\n\n\n

Q: Can a small biotech negotiate a favorable royalty rate against a large pharma partner if its patent estate is still pending rather than granted?<\/strong><\/p>\n\n\n\n

Pending composition-of-matter applications with broad, well-supported claims, filed in major jurisdictions and showing a clean prosecution history without office action rejections, carry substantial value. The risk premium applied to pending versus granted status is negotiable, particularly if the application is advanced in prosecution, has received an allowance, or has granted equivalents in some jurisdictions. The most effective approach is to demonstrate to the partner that the claims are likely to be granted substantially as filed: share the examiner’s search report or office action response to show the prosecution trajectory.<\/p>\n\n\n\n

Q: What is the impact of the Inflation Reduction Act drug price negotiation provisions on patent-based exclusivity strategy?<\/strong><\/p>\n\n\n\n

The IRA’s Medicare price negotiation provisions apply to small molecule drugs 9 years after first approval and biologics 13 years after first approval. This effectively shortens the commercially relevant exclusivity window for Medicare-covered products beyond what patent expiration alone would suggest. For lifecycle management strategy, the IRA changes the calculus on indication expansion and secondary patenting: a new indication filed in year 8 that adds 3 years of patent coverage does not provide 3 additional years of full commercial exclusivity if the product enters Medicare price negotiation before those patents expire. IP strategy teams need to model the interaction between patent expiration timelines and IRA negotiation eligibility dates in their lifecycle planning.<\/p>\n\n\n\n

Q: How do you use patent data to identify M&A targets before they run a formal process?<\/strong><\/p>\n\n\n\n

The signals that indicate a biotech is preparing for a transaction include: accelerated national phase filings across multiple jurisdictions (indicating a company moving from priority filing to global protection as it prepares a data room), new Orange Book or Purple Book submissions (indicating commercial readiness), and a recent expansion of the secondary patent estate with formulation or manufacturing patents (indicating the company is building the IP narrative that a buyer’s due diligence team will scrutinize). Overlaying these patent signals with clinical trial completion dates, PDUFA dates for pending NDA applications, and known BD&L conference participation creates a probability-weighted M&A calendar that identifies likely targets before their investment bankers begin formal outreach.<\/p>\n\n\n\n

\n\n\n\n

Data references: DiMasi et al., Journal of Health Economics (2016); BIO Clinical Development Success Rates (2022); Scannell et al., Nature Reviews Drug Discovery (2012); BPCIA statute and FDA guidance documents; Thaler v. Vidal, Federal Circuit (2022); Hatch-Waxman Act and Orange Book guidance; CNIPA filing statistics, WIPO IP Statistics Data Center.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough The cost to bring a new molecular entity […]<\/p>\n","protected":false},"author":1,"featured_media":34567,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-34080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=34080"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34080\/revisions"}],"predecessor-version":[{"id":38149,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34080\/revisions\/38149"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34567"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=34080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=34080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=34080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}